This is a working overview of HPLC, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-08-25 and is reviewed periodically as new material appears.
Whether the drug improves hard clinical outcomes is not settled. No completed trial has shown a reduction in heart attacks or strokes among treated patients, although a dedicated cardiovascular outcomes study has been discussed in the literature. Investigators have also examined hepatic fat in people with HIV and fatty liver disease, cognitive measures in small cohorts, and changes in bone density. Regulatory labeling emphasizes monitoring of insulin-like growth factor 1 because supraphysiologic levels raise questions about tissue growth, and the clinical significance of that signal remains an open question rather than a demonstrated harm.
Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized cake in single-use vials |
| Solubility class | Freely soluble in water | Reconstituted with sterile diluent before injection |
| Typical storage temperature | 2 to 8 degrees Celsius | Before reconstitution; protect from light |
| Typical analytical method | Reversed-phase high-performance liquid chromatography | Purity and related-substance testing |
| Identity confirmation | Mass spectrometry | Observed mass near 5.1 kDa for the intact peptide |
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass and detects chemical modifications. Peptide mapping and amino acid analysis can verify sequence integrity. Water content is measured by Karl Fischer titration, and residual solvents may be checked by gas chromatography. These methods together support batch-to-batch consistency and routine quality control.
Lyophilized tesamorelin is generally stored refrigerated at temperatures between 2 and 8 degrees Celsius. The solid form is comparatively stable when kept dry and protected from light. Moisture uptake can promote aggregation and degradation, so sealed containers with desiccant are common. Researchers typically avoid repeated temperature cycling, which may stress the peptide. Documentation accompanying reference materials usually specifies a shelf life under these conditions.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
The mechanism of action on a cellular level is not well understood. However, it has been shown that binding of different sugars to the glucose site affects the orientation of the aglycone in the access vestibule. So when the aglycone binds, it affects the entire inhibitor. Together, these mechanisms lead to a synergistic interaction. Therefore, variations in the structure of both the sugar and the aglycone are crucial for the pharmacophore of SGLT inhibitors. Dapagliflozin is an example of an SGLT-2 inhibitor; it is a competitive, highly selective inhibitor of SGLT. It acts via selective and potent inhibition of SGLT-2, and its activity is based on each patient's underlying blood sugar control and kidney function. The results are decreased kidney reabsorption of glucose, glucosuria effect increases with higher levels of glucose in the blood circulation. Therefore, dapagliflozin reduces the blood glucose concentration with a mechanism that is independent of insulin secretion and sensitivity, unlike many other antidiabetic medications. Functional pancreatic β-cells are not necessary for the activity of the medication, so it is convenient for patients with diminished β-cell function. Sodium and glucose are co-transported by the SGLT-2 protein into the tubular epithelial cells across the brush-border membrane of the proximal convoluted tubule. This happens because of the sodium gradient between the tubule and the cell, and therefore provides a secondary active transport of glucose.
=== Organisation (Pre-2018) === Transportation Corps Headquarters Logistics office - Headquarters in 21 Huixin West Street, Chaoyang district, Beijing 1st Transportation Corps 1st Transportation Detachment 2nd Transportation Detachment 3rd Transportation Detachment 2nd Transportation Corps - Headquartered in Kashgar 4th Transportation Detachment 5th Transportation Detachment 6th Transportation Detachment 7th Transportation Detachment - Headquartered in Qinhuangdao 8th Transportation Detachment - Jurisdiction area Xinjiang-Tibet Highway between Rutog County and Saga County
== External links == Academy of Managed Care Pharmacy American College of Clinical Pharmacy Board of Pharmacy Specialties Journal of Clinical Pharmacy and Therapeutics The British Journal of Clinical Pharmacy United Kingdom Clinical Pharmacy Association Clinical Pharmacy Education, Practice and Research
==== Peptides ==== Prebiotic peptide synthesis could have occurred by several routes. Some center on high temperature/concentration conditions in which condensation becomes energetically favorable, while others use plausible prebiotic condensing agents. Experimental evidence for the formation of peptides in uniquely concentrated environments is bolstered by work suggesting that wet-dry cycles and the presence of specific salts can greatly increase spontaneous condensation of glycine into poly-glycine chains. Other work suggests that while mineral surfaces, such as those of pyrite, calcite, and rutile catalyze peptide condensation, they also catalyze their hydrolysis. The authors suggest that additional chemical activation or coupling would be necessary to produce peptides at sufficient concentrations. Thus, mineral surface catalysis, while important, is not sufficient alone for peptide synthesis. Many prebiotically plausible condensing/activating agents have been identified, including the following: cyanamide, dicyanamide, dicyandiamide, diaminomaleonitrile, urea, trimetaphosphate, NaCl, CuCl2, (Ni,Fe)S, CO, carbonyl sulfide (COS), carbon disulfide (CS2), SO2, and diammonium phosphate (DAP). A 2024 experiment used a sapphire substrate with a web of thin cracks under a heat flow, mimicking deep-ocean vents, to concentrate prebiotically relevant building blocks from a dilute mixture by up to three orders of magnitude. This could help to create biopolymers such as peptides.
== Clinical research == The feasibility of using recombinant human tropoelastin to promote elastin-fibre production and improve skin flexibility in wounds and scars has been studied. Although new elastin fibres were observed following the administration of recombinant human tropoelastin into fresh wounds, the treatment did not result in significant improvements in scar appearance or flexibility. Another line of research has investigated stimulation of endogenous elastin production in the skin. In an in vitro study, an amino acid–copper mixture increased elastin- and type I collagen-related gene expression and protein production in cultured human dermal fibroblasts compared with copper or the amino acid mixture alone. A subsequent open-label, single-centre clinical study evaluated a skin-booster formulation containing amino acids, copper sulfate and non-cross-linked hyaluronic acid, marketed as Elastic Lab. Five participants received four facial treatments at one-week intervals, and the outcomes were assessed one week after the final treatment. Instrumentally measured skin elasticity increased by 23.4% from baseline, while skin thickness and density increased by 7.3% and 12.5%, respectively. Improvements in skin hydration and periocular wrinkle depth were also reported. The study did not directly measure newly synthesised or deposited elastin fibres.
Sources: en.wikipedia.org
== Application == Knowing the direction of Langer's lines within a specific area of the skin is important for surgical operations, particularly cosmetic surgery. If a surgeon has a choice about where and in what direction to place an incision, they may choose to cut in the direction of Langer's lines. Incisions made parallel to Langer's lines may heal better and produce less scarring than those that cut across. Conversely, incisions perpendicular to Langer's lines have a tendency to pucker and remain obvious, although sometimes this is unavoidable. The orientation of stab wounds relative to Langer's lines can have a considerable impact upon the presentation of the wound. Langer's lines include breast static tension lines, which mark a guide for breast surgery incisions. Keloids are more common when incision is given across Langer's lines. Sometimes the exact direction of the collagen fibers are unknown, because in some regions of the body there are differences between different individuals.
=== Isotope preparation === Curium is made in small amounts in nuclear reactors, and by now only kilograms of 242Cm and 244Cm have been accumulated, and grams or even milligrams for heavier isotopes. Hence the high price of curium, which has been quoted at 160–185 USD per milligram, with a more recent estimate at US$2,000/g for 242Cm and US$170/g for 244Cm. In nuclear reactors, curium is formed from 238U in a series of nuclear reactions. In the first chain, 238U captures a neutron and converts into 239U, which via β− decay transforms into 239Np and 239Pu.
Many AI systems are so complex that their designers cannot explain how they reach their decisions. Particularly with deep neural networks, in which there are many non-linear relationships between inputs and outputs. But some popular explainability techniques exist. It is impossible to be certain that a program is operating correctly if no one knows how exactly it works. There have been many cases where a machine learning program passed rigorous tests, but nevertheless learned something different from what the programmers intended. For example, a system that could identify skin diseases better than medical professionals was found to actually have a strong tendency to classify images with a ruler as "cancerous", because pictures of malignancies typically include a ruler to show the scale. Another machine learning system designed to help effectively allocate medical resources was found to classify patients with asthma as being at "low risk" of dying from pneumonia. Having asthma is actually a severe risk factor, but since the patients having asthma would usually get much more medical care, they were relatively unlikely to die according to the training data. The correlation between asthma and low risk of dying from pneumonia was real, but misleading. People who have been harmed by an algorithm's decision have a right to an explanation. Doctors, for example, are expected to clearly and completely explain to their colleagues the reasoning behind any decision they make.
In the 1826 General Convention of Friendship, Commerce and Navigation with the king of Denmark, the United States recognised Greenland as a northern possession of the king, and accepted the trade restrictions that Denmark imposed there. In the Treaty of the Danish West Indies, signed in 1916, the US government explicitly recognised Danish sovereignty over all of Greenland. In the 1941 US–Danish agreement, the American Government "reiterate[d] its recognition of and respect for the sovereignty of the Kingdom of Denmark over Greenland". During World War II, the United States defended Greenland at the request of Danish and Greenlandic officials acting without approval from the central government of Denmark, while it was under Nazi occupation. In the 1951 Greenland Defense Agreement, the United States again recognised the sovereignty of the Kingdom of Denmark over all of Greenland. In the 2004 amendment to the Greenland Defense Agreement, the United States recognised Greenland as "an equal part of the Kingdom of Denmark under the Constitution [with] a wide ranging Greenland Home Rule".
=== Role in muscle regeneration === The first step to understanding the importance of macrophages in muscle repair, growth, and regeneration is that there are two "waves" of macrophages with the onset of damageable muscle use– subpopulations that do and do not directly have an influence on repairing muscle. The initial wave is a phagocytic population that comes along during periods of increased muscle use that are sufficient to cause muscle membrane lysis and membrane inflammation, which can enter and degrade the contents of injured muscle fibers. These early-invading, phagocytic macrophages reach their highest concentration about 24 hours following the onset of some form of muscle cell injury or reloading. Their concentration rapidly declines after 48 hours. The second group is the non-phagocytic types that are distributed near regenerative fibers. These peak between two and four days and remain elevated for several days while muscle tissue is rebuilding. The first subpopulation has no direct benefit to repairing muscle, while the second non-phagocytic group does. It is thought that macrophages release soluble substances that influence the proliferation, differentiation, growth, repair, and regeneration of muscle, but at this time the factor that is produced to mediate these effects is unknown. It is known that macrophages' involvement in promoting tissue repair is not muscle specific; they accumulate in numerous tissues during the healing process phase following injury.
Sources: en.wikipedia.org
It mimics a natural hypothalamic signal that tells the pituitary to release growth hormone. The result is a rise in circulating growth hormone and, indirectly, in insulin-like growth factor 1. Over weeks of treatment this shift is associated with a selective decrease in fat stored inside the abdomen.
The primary measure is usually a cross-sectional abdominal scan that separates internal fat from fat just under the skin. Waist circumference and body weight are recorded as secondary measures because they are easy to obtain but do not distinguish the two fat compartments. Hormone and metabolic blood tests are collected alongside the imaging.
Available follow-up data indicate that visceral fat drifts back toward pretreatment levels once injections stop. The change is therefore best described as treatment-dependent rather than permanent. Investigators continue to debate whether intermittent or repeated courses would preserve any benefit.
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.